Related Articles
New Insights & Approvals for Baricitinib
New research shows that baricitinib is a safe and effective RA treatment. The medication has also been approved for use in Japan and is recommended for use in the U.K…
Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA
Brodalumab Approved for Plaque Psoriasis The U.S. Food and Drug Administration has approved brodalumab, a monoclonal antibody that targets interleukin 17 (IL‑17).1,2 Brodalumab (Siliq) was approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond to, or have lost response to, other…
Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA
In a recent study, baricitinib proved more effective than adalimumab in treating adults with RA through 52 weeks…
FDA Update: Biosiomilar to Adalimumab Receives FDA Approval
The FDA has approved adalimumab-adbm, a biosimilar, to treat multiple chronic inflammatory diseases…